Combining Association Tests across Multiple Genetic Markers in Case-Control Studies

2008 ◽  
Vol 65 (3) ◽  
pp. 166-174 ◽  
Author(s):  
Huanyu Zhou ◽  
Lee-Jen Wei ◽  
Xiping Xu ◽  
Xin Xu
2020 ◽  
Author(s):  
Lin Zhang ◽  
Lei Sun

AbstractIn a case-control association study, deviation from Hardy-Weinberg equilibrium (HWE) or Hardy-Weinberg dis-equilibrium (HWD) in the control group is usually considered as evidence for potential genotyping error, and the corresponding SNP is then removed from the study. On the other hand, assuming HWE holds in the study population, a truly associated SNP is expected to be out of HWE in the case group. Efforts have been made in combining association tests with tests of HWE in the cases to increase the power of detecting disease susceptibility loci (Song and Elston (2006), Wang and Shete (2010)). However, these existing methods are ad-hoc and sensitive to model assumptions. Utilizing the recent robust allele-based (RA) regression model for conducting allelic association tests (Zhang and Sun (2020)), here we propose a joint RA test that naturally integrates association evidence from the traditional association test and a test that evaluates the difference in HWD between the case and control groups. The proposed test is robust to genotyping error, as well as to potential HWD in the population attributed to factors that are unrelated to phenotype-genotype association. We provide the asymptotic distribution of the proposed test statistic so that it is easy to implement, and we demonstrate the accuracy and efficiency of the test through extensive simulation studies and an application.


2002 ◽  
Vol 53 (3) ◽  
pp. 146-152 ◽  
Author(s):  
Boris Freidlin ◽  
Gang Zheng ◽  
Zhaohai Li ◽  
Joseph L. Gastwirth

2010 ◽  
Vol 70 (3) ◽  
pp. 167-176 ◽  
Author(s):  
Andrew S. Allen ◽  
Glen A. Satten ◽  
Sarah L. Bray ◽  
Frank Dudbridge ◽  
Michael P. Epstein

Author(s):  
Ruth H. Keogh ◽  
D. R. Cox

1976 ◽  
Vol 35 (01) ◽  
pp. 049-056 ◽  
Author(s):  
Christian R Klimt ◽  
P. H Doub ◽  
Nancy H Doub

SummaryNumerous in vivo and in vitro experiments, investigating the inhibition of platelet aggregation and the prevention of experimentally-induced thrombosis, suggest that anti-platelet drugs, such as aspirin or the combination of aspirin and dipyridamole or sulfinpyrazone, may be effective anti-thrombotic agents in man. Since 1971, seven randomized prospective trials and two case-control studies have been referenced in the literature or are currently being conducted, which evaluate the effects of aspirin, sulfinpyrazone, or dipyridamole in combination with aspirin in the secondary prevention of myocardial infarction. A critical review of these trials indicates a range of evidence from no difference to a favorable trend that antiplatelet drugs may serve as anti-thrombotic agents in man. To date, a definitive answer concerning the therapeutic effects of these drugs in the secondary prevention of coronary heart disease is not available.


Sign in / Sign up

Export Citation Format

Share Document